Covid19

Results From Phase 3 Trials of AZD7442 Show Robust Efficacy of Prevention and Treatment …

The results showed that one 300 mg dose of AZD7442 reduced the risk of developing symptomatic COVID-19 by 83% and one 600 mg dose reduced the risk …

Read more at www.pharmacytimes.com

Show More

Related Articles

Back to top button